Table 3.
PCC consult | No PCC consult | Difference in mean or prevalence | |
---|---|---|---|
N (%) | 295 (67.8) | 140 (32.2) | 35.6 |
Mean age (95% CI) | 29.2 (27.4, 31.1) | 28.8 (26.2, 31.5) | 0.4 (−2.9, 3.7) |
Females (%) | 215 (72.9) | 104 (74.3) | 1.4 |
Mean LOS in hours (95% CI) | 61.9 (57.2, 66.5) | 76.3 (66.6, 86.0) | 14.4 (5.0, 23.9) |
Mean ED LOS in hours (95% CI) | 6.1 (5.5, 6.7) | 5.3 (4.8, 5.9) | 0.8 (−0.2, 1.7) |
Mean lab clearance to discharge in hours (95% CI) | 33.1 (29.3, 36.9) | 39.4 (31.9, 47.0) | 6.3 (−1.2, 13.9) |
Mean TOI to presentation in hours (95% CI) | 10.0 (8.2, 11.9) | 8.9 (6.9, 10.8) | 1.2 (−2.4, 4.7) |
Ingestion type | |||
Accidental (%) | 46 (15.7) | 22 (15.7) | 0 |
Intentional (%) | 245 (83.3) | 114 (81.4) | 1.9 |
Unknown (%) | 3 (1.0) | 4 (2.9) | 1.9 |
Co-ingestants (%) | 155 (52.7) | 65 (46.4) | 6.3 |
Mean TOI to NAC (95% CI) | 12.6 (10.4, 14.9) | 11.5 (9.2, 13.9) | 1.1 (−2.6, 4.8) |
IV NAC (%) | 74 (25.1) | 29 (21.2) | 3.9 |
SDAC in ED (%) | 139 (32.0) | 70 (16.1) | 15.9 |
Patients with liver enzyme elevation (%) | 94 (31.9) | 51 (36.4) | 4.5 |
Significant liver enzyme elevation (%)a | 39 (13.2) | 24 (17.1) | 3.9 |
Patients with highest recorded INR > 1.3 (%)b | 45 (17.0) | 32 (25.6) | 8.6 |
Transfer for OLT/Received OLT (%) | 3/0 (1.0) | 5/0 (3.6) | 2.6 |
Deaths (%) | 1 (0.3) | 3 (2.1) | 1.8 |
Nomogram placementc | |||
Above “200” line (%) | 105 (53.3) | 56 (60.9) | 7.6 |
Between “150” and “200” lines (%) | 32 (16.2) | 19 (20.7) | 4.5 |
Below “150” line (%) | 60 (30.5) | 17 (18.5) | 12.0 |
Mean highest APAP level (95% CI) | 101.0 (91.7, 110.4) | 119.0 (105.0, 133.0) | 18.0 (1.38, 34.5) |
LOS length of stay, TOI time of ingestion, PCC poison control center, NAC N-acetylcysteine, AC activated charcoal, OLT orthotopic liver transplantation
aSignificant liver enzyme elevation is defined as AST and/or ALT >1,000 IU/L
bOf cases with recorded INR
cOf cases appropriate for Rumack–Matthews nomogram placement